"It feels like glass running through your veins." Faith Adjei-Sarpong lives with sickle cell disease and, like many others ...
Sickle cell disease—the subject of a new Seminar in The Lancet—is one of the most prevalent and fastest-growing genetic ...
Sickle cell disease specialists face higher burnout rates than peers, impacting patient care and highlighting the need for ...
LOS ANGELES (KABC) -- It's been more than a month since the FDA approved two milestone gene-editing treatments for sickle cell disease, but lining up patients for these therapies will be a challenge ...
Female adolescents and adults with sickle cell disease are at risk for a range of menstrual complications, especially pain and abnormal uterine bleeding. That’s according to the authors of a new multi ...
On average, patients included in the audit are taking nearly six medications, reflecting a high degree of polypharmacy and complex chronic disease management typical of moderate-to-severe sickle cell ...
A new study finds that only one in three patients visiting emergency departments (EDs) for severe pain associated with sickle cell disease received appropriate opioid-based pain-relieving medications ...
Beam Therapeutics, based in Cambridge, Mass., released early clinical data from its first trial for patients with sickle cell disease that employed a gene editing tool, known as CRISPR. All four ...
Andrea Matthews poses with her son Jonathan Matthews. She started the foundation because her son lives with sickle cell disease. Michelle Parr's sickle cell disease went undiagnosed for 25 years. Her ...
This month the WISN 12's "Day of Giving" campaign benefits Versiti, a nonprofit dedicated to saving lives through blood donations and furthering the research needed to improve patients' health. One ...
Hundreds met at Union Point Park to lace up their tennis shoes for a good cause. The 5K “March for sickle cell in New Bern” ...
A sickle cell emergency unit at the Royal London Hospital in Whitechapel will remain open following a campaign, it has been ...